SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Sun Pharmaceutical Industries
Sun Pharmaceutical Industries
BSE: 524715|NSE: SUNPHARMA|ISIN: INE044A01036|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Sep 02, 16:00
863.15
21.05 (2.5%)
VOLUME 159,569
LIVE
NSE
Sep 02, 15:54
863.55
21.2 (2.52%)
VOLUME 1,949,092
Earnings News on Sun Pharmaceutical Industries
Select Year: 2013 |  2012 |  2011 | 2010 | 2009 | 2008 | 2007 | 2000-2006
Maintain 13-15% growth guidance for full year: Sun Pharma 

3.33 pm | 13 Aug 2014 |  Source: CNBC-TV18

According to Uday Baldota, people should not focus too much on one-time sales of the company as Sun Pharma is confident of achieving its full year gui...

Sun Pharma posts Q1 profit at Rs 1,390 cr 

8.14 am | 13 Aug 2014 |  Source: PTI

Net sales of the company rose to Rs 3,926.85 crore for the first quarter, as compared to Rs 3,482.18 crore in the same period of previous fiscal, Sun ...

Sun Pharma Q1 net seen up 8% at Rs 1342.3 cr: Emkay

12.34 pm | 12 Aug 2014 |  Source: Moneycontrol.com

Sales are expected to increase by 7 percent Q-o-Q (up 24 percent Y-o-Y) to Rs 4342.9 crore, according to Emkay Global Financial Services....

Sun Pharma Q1 adjusted profit may grow 13.2% to Rs 1405 cr 

5.40 pm | 11 Aug 2014 |  Source: CNBC-TV18

Revenue is seen going up by 17.5 percent to Rs 4,115 crore during the quarter from Rs 3,503 crore in the year-ago period driven by US sales....

Dr Reddy's, Lupin, Glenmark top pharma bets: Nomura 

11.25 am | 31 Jul 2014 |  Source: CNBC-TV18

"We have a buy recommendation on both Sun Pharma and Ranbaxy at this point," Saion Mukherjee, research analyst Nomura said....

Ranbaxy Q1 disappoints, posts loss at Rs 186cr on provision 

5.14 pm | 29 Jul 2014 |  Source: CNBC-TV18

Consolidated revenue of the company fell 9.6 percent on yearly basis to Rs 2,426.2 crore due to lower exports (declined over 13 percent) while domesti...

Ranbaxy Labs may post Q1 profit Rs 27 cr vs loss YoY: Poll 

6.15 pm | 28 Jul 2014 |  Source: CNBC-TV18

Analysts feel operating profit (EBITDA) may be impacted due to consent decree costs that is expected to be in single digits. They expect mark-to-marke...

1
Quick Links for Sun Pharmaceutical Industries
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.